Next-wave radiopharmaceuticals: insights from AACR

Readouts at AACR reflect radiopharmaceuticals’ ongoing expansion beyond its most established radioisotopes, targets and ligand modalities. While most of these programs are still early stage, data presented at the conference suggest the field is poised to grow its understanding of who benefits from these therapies, and who is at greater risk for tox.

A wider range of patients are being treated with targeted radiopharmaceuticals — both via new targets, and via expanding indications around anchor targets, such as the Tuesday’s approval of Lutathera 177Lu-Dotatate for pediatric gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Among the questions the field is tracking is how the modality behaves in different patient subsets...